Helen X. Chen

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

James Chih‐Hsin Yang, Leah Haworth, Richard M. Sherry et al. · New England Journal of Medicine · 2003 · 2.7K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak et al. · New England Journal of Medicine · 2010 · 1.8K citations · Full text

Medicine, Immunology, Oncology +14

Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study

Christopher G. Willett, Dan G. Duda, Emmanuelle di Tomaso et al. · Journal of Clinical Oncology · 2009 · 507 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski et al. · Journal of Clinical Oncology · 2022 · 439 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study

Leonard B. Saltz, Heinz‐Josef Lenz, Hedy L. Kindler et al. · Journal of Clinical Oncology · 2007 · 427 citations · Full text

Medicine, Oncology, Pharmacology +14